Citigroup’s FibroBiologics FBLG Stock Holding History

Citigroup’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1	Buy	+1	New	+$1	﹤0.01%	5960
2025 Q3	–	Sell	-9	Closed	-$106	–	6355
2025 Q2	$106	Sell	9 -965	-99%	-$17.4K	﹤0.01%	5511
2025 Q1	$17.5K	Sell	974 -121	-11%	-$3.46K	﹤0.01%	5114
2024 Q4	$43.8K	Buy	1,095 +93	+9%	+$4.99K	﹤0.01%	5120
2024 Q3	$61.9K	Buy	1,002 +707	+240%	+$47K	﹤0.01%	4955
2024 Q2	$29.5K	Sell	295 -1,226	-81%	-$234K	﹤0.01%	4875
2024 Q1	$329K	Buy	+1,521	New	+$366K	﹤0.01%	3790

Other funds holding FBLG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Grove Bank & Trust Miami, Florida $1.01B AUM 19.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Citigroup's FBLG Position: Q3 2026 in Review

Citigroup opened a new position in FibroBiologics (FBLG) in Q3 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5960 among its holdings. This is a return to the name: Citigroup previously reported a position in FBLG as recently as Q2 2025.

Citigroup first reported a position in FBLG in Q1 2024 and has held it in 7 quarters since. The position peaked at $329K in Q1 2024. 6 funds tracked by Wall St. Rank hold FBLG as of Q3 2026.

Citigroup held 1 share of FibroBiologics worth $1 as of Q3 2026.
FibroBiologics was a new Citigroup position in Q3 2026.
FibroBiologics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5960 holding.
Citigroup first reported a position in FibroBiologics in Q1 2024 and has held it in 7 quarters since.
Citigroup's FibroBiologics position peaked at $329K in Q1 2024.
6 funds tracked by Wall St. Rank held FibroBiologics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.